Bacillus Calmette-Guerin (BCG) by the University of Melbourne and AZD1222 by The University of Oxford are the two vaccines now in Phase II-III interventional trial. mRNA-1273 by the American biotech company Moderna is in Phase II efficacy and dose-testing studies. China's Sinovac Biotech is set to become the third later this month.
Russian Federation has become the first nation to complete a COVID-19 human vaccine clinical trial successfully. The all round selection of worldwide COVID-19 conditions was nearing 12.7 million, when the fatalities have increased to much more than 564,000, in accordance to Johns Hopkins University in the US.
Results for Phase 1 are expected to be available after about three months, with plans to progress to the next stage of trials as soon as possible.
In the Russian vaccine trials, the first stage of research on the vaccine began on 18 June when a group of 18 volunteers were vaccinated.
The group did not experience any significant side effects and is due to be released from hospital on Wednesday, RIA reported on Sunday, citing a director at the Sechenov University in Moscow where the trial took place.
Over a dozen experimental vaccines are being trialled around the world, as the pandemic continues to spread. Before, benefits of the COVID-19 vaccine exams performed on a team of volunteers in Russian Federation confirmed that they had been building immunity to the coronavirus. The vaccine should now get the approvals for mass production.
Tarasov added that the first group of volunteers would be discharged on July 15, 2020, followed by the second group on July 20th.
"The research has been completed and it proved that the vaccine is safe".
The main objective of the first stage of the study "was to show the vaccine's safety on humans, which was successfully done", said Alexander Lukashev, the director of the Institute of Medical Parasitology, Tropical, and Vector-Borne Diseases at Sechenov University to Sputnik.
The vaccine candidate was developed by Viroclinics Xplore and uses molecular clamp technology to "lock the "spike" protein into a shape which allows the immune system to be able to recognise and then neutralise the virus".
The apex body pinned hopes on the one being developed by Oxford, labeling it as the "most advanced".